AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

genOway

CR
Bloomberg   ALGEN FP
Biomedical-Genetics  /  France  Web Site   |   Investors Relation
We have stopped researching genOway from 1 September 2019.